Sana biotechnology announces positive clinical results from type 1 diabetes study of islet cell transplantation without immunosuppression

First-in-human study provides evidence that sana's hypoimmune (hip) technology enables transplanted islet cells to avoid immune rejection and produce insulin without immunosuppression

SANA Ratings Summary

SANA Quant Ranking